Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to outsmart resistant lung cancer

NCT ID NCT04988295

Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 21, 2026 · Updated 6 times

Summary

This phase 3 trial tests whether adding two targeted drugs (amivantamab and lazertinib) to standard chemotherapy can help people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) whose cancer has stopped responding to the drug osimertinib. About 776 participants will receive either the drug combo plus chemo or chemo alone. The main goal is to see if the combo delays cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
amivantamab and lazertinib (targeted drugs) plus platinum-based chemotherapy
What this could lead to
If successful, this combination could offer a new treatment option for people with a specific type of lung cancer that has stopped responding to current therapy, potentially extending time without cancer growth.
What could go wrong
This is a late-stage trial, but results are not yet final. The added drugs may cause more side effects, and the benefit over standard chemo alone is not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

776 people

The number who actually took part.

Started

Nov 2021

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant must have at least 1 measurable lesion, according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, that has not been previously irradiated * Participant must have histologically or cytologically confirmed, locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC), characterized at or after the time of locally advanced or metastatic disease diagnosis by either epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R mutation * A participant with a history of brain metastases must have had all lesions treated as clinically indicated (that is, no current indication for further definitive local therapy). Any definitive local therapy to brain metastases must have been completed at least 14 days prior to randomization and the participant can be receiving no greater than10 milligrams (mg) prednisone or equivalent daily for the treatment of intracranial disease * Participant must have Eastern Cooperative Oncology Group (ECOG) status of 0 or 1 * Any toxicities from prior systemic anticancer therapy must have resolved to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0 Grade 1 or baseline level (except for alopecia \[any grade\], Grade \<= 2 peripheral neuropathy, or Grade \<= 2 hypothyroidism stable on hormone replacement) * A participant of childbearing potential must have a negative serum pregnancy test at screening and within 72 hours of the first dose of study treatment and must agree to further serum or urine pregnancy tests during the study * Participant must have progressed on or after osimertinib monotherapy as the most recent line of treatment. Osimertinib must have been administered as either the first-line treatment for locally advanced or metastatic disease or in the second- line setting after prior treatment with first- or second-generation EGFR tyrosine kinase inhibitor (TKI) as a monotherapy. Participants who received either neoadjuvant and/or adjuvant treatment of any type are eligible if progression to locally advanced or metastatic disease occurred at least 12 months after the last dose of such therapy and then the participant progressed on or after osimertinib in the locally advanced or metastatic setting. Treatment with osimertinib must be discontinued at least 8 days (4 half-lives) prior to randomization (that is last dose no later than Day -8) Exclusion Criteria: * Participant received radiotherapy for palliative treatment of NSCLC less than 14 days prior to randomization * Participant with symptomatic or progressive brain metastases * Participant has history of or current evidence of leptomeningeal disease, or participant has spinal cord compression not definitively treated with surgery or radiation * Participant has known small cell transformation * Participant has a medical history of interstitial lung disease (ILD), including drug-induced ILD or radiation pneumonitis * Participant has a history of clinically significant cardiovascular disease including, but not limited to diagnosis of deep vein thrombosis or pulmonary embolism within 4 weeks prior to randomization; myocardial infarction; unstable angina; stroke; transient ischemic attack; coronary/peripheral artery bypass graft; or acute coronary syndrome. Participant has a significant genetic predisposition to venous thromboembolic events. Participant has a prior history of venous thromboembolic events and is not on appropriate therapeutic anticoagulation as per National Comprehensive Cancer Network or local guidelines

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carcinoma, non-small-cell lung are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carcinoma, non-small-cell lung

Contacts and locations

Locations

  • Adana City Hospital

    Adana, 01060, Turkey (Türkiye)

  • Affiliated Hospital of North Sichuan Medical College

    Nanchong, 637503, China

  • Akademiska Sjukhuset

    Uppsala, 75181, Sweden

  • Alliance Cancer Specialists

    Horsham, Pennsylvania, 19044, United States

  • Ankara Bilkent City Hospital

    Ankara, 06800, Turkey (Türkiye)

  • Arizona Oncology Associates

    Tucson, Arizona, 85711, United States

  • Artemis Hospital

    Gurugram, 122001, India

  • Arthur J E Child Comprehensive Cancer Centre

    Calgary, Alberta, T2N 5G2, Canada

  • Asan Medical Center

    Seoul, 05505, South Korea

  • Asklepios Klinikum Harburg

    Hamburg, 21075, Germany

  • Associacao Hospitalar Moinhos de Vento

    Porto Alegre, 90035-001, Brazil

  • Astera Cancer Care

    East Brunswick, New Jersey, 08816, United States

  • Azienda Ospedaliero-Universitaria Di Parma

    Parma, 43126, Italy

  • Bakirkoy Training and Research Hospital

    Istanbul, 34147, Turkey (Türkiye)

  • Baptist Cancer Center

    Memphis, Tennessee, 38120, United States

  • Beacon Hospital Sdn Bhd

    Petaling Jaya, 46050, Malaysia

  • Beijing Cancer Hospital

    Beijing, 100142, China

  • Beijing Cancer Hospital Chest Tumor Internal Medicine dept. II

    Beijing, 100142, China

  • Beijing Chest hospital, Capital medical university

    Beijing, 101199, China

  • Bethanien Krankenhaus

    Moers, 47441, Germany

  • Bhaktivedanta Hospital & Research Institute

    Thane, 411107, India

  • Blue Ridge Cancer Care

    Wytheville, Virginia, 24382, United States

  • British Columbia Cancer Agency

    Vancouver, British Columbia, V5Z 4E6, Canada

  • CEMIC (Centro de Educación Médica e Investigaciones Clínicas)

    CABA, C1431FWO, Argentina

  • CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia

    Santo André, 09060 650, Brazil

  • CHA Bundang Medical Center, CHA University

    Gyeonggi-do, 13496, South Korea

  • CHR Hôpital Calmette

    Lille, 59000, France

  • CHRU Hopital de Pontchaillou

    Rennes, 35033, France

  • CHU Bordeaux

    Pessac, 33604, France

  • CHU Bretonneau

    Tours, 37000, France

  • CHU Nantes

    Sain-Herblain, 44800, France

  • CHU Sart-Tilman

    Liège, 4000, Belgium

  • CHU de Grenoble Hopital Albert Michallon

    La Tronche, 38700, France

  • CHU de Montpellier - Arnaud de Villeneuve

    Montpellier, 34295, France

  • CIMOVA, Morals Vargas Centro de Investigación SC

    León, 37000, Mexico

  • CINME Centro de Investigaciones Metabolicas

    Caba, C1027AAP, Argentina

  • CIONC Centro Integrado de Oncologia de Curitiba

    Curitiba, 80810 050, Brazil

  • COT - Centro Oncologico do Triangulo S.A

    Uberlândia, 38408-150, Brazil

  • CRO IRCCS Istituto Nazionale Tumori

    Aviano, 33081, Italy

  • Cancer Hospital Chinese Academy of Medical Sciences

    Shenzhen, 518116, China

  • Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, 100021, China

  • Cedars Sinai Medical Center

    Los Angeles, California, 90048, United States

  • Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica

    Córdoba, 5000, Argentina

  • Centre Hospitalier du Mans

    Le Mans, 72000, France

  • Centro Medico Fleischer

    CABA, C1414, Argentina

  • Centrum Onkologii im Prof F Lukaszczyka

    Bydgoszcz, 85 796, Poland

  • Cetus Oncologia

    Belo Horizonte, 30110-017, Brazil

  • Chaim Sheba Medical Center

    Ramat Gan, 5262100, Israel

  • Changhua Christian Hospital

    Changhua, 500, Taiwan

  • Chinese PLA General Hospital

    Beijing, 100853, China

  • Chongqing University Cancer Hospital

    Chongqing, 400000, China

  • Chung Shan Medical University Hospital

    Taichung, 402, Taiwan

  • City Clinical Hospital #1

    Nal'chik, 360000, Russia

  • City of Hope

    Duarte, California, 91010, United States

  • Clinica Univ. de Navarra

    Pamplona, 31008, Spain

  • Clinique Saint Pierre

    Ottignies, 1340, Belgium

  • Clínica Viedma

    Viedma, R8500ACE, Argentina

  • Compass Oncology

    Vancouver, Washington, 98684, United States

  • Daping Hospital Army Characteristic Medical Center

    Chongqing, 400042, China

  • Edinburgh Cancer Centre Western General

    Edinburgh, EH4 2XU, United Kingdom

  • Ehime University Hospital

    Toon-shi, 791-0295, Japan

  • Erasmus MC

    Rotterdam, 3015 GD, Netherlands

  • Evangelische Lungenklinik Berlin

    Berlin, 13125, Germany

  • Fakultni nemocnice Olomouc - I.P.Pavlova 6

    Olomouc, 775 20, Czechia

  • Fakultni nemocnice Plzen

    Pilsen, 30599, Czechia

  • Fudan University Shanghai Cancer Center

    Shanghai, 200032, China

  • Fundacao Antonio Prudente A C Camargo Cancer Center

    São Paulo, 01509 900, Brazil

  • Fundacao Sao Francisco Xavier

    Ipatinga, 35162 189, Brazil

  • Gazi University Hospital

    Ankara, 06560, Turkey (Türkiye)

  • Goztepe Prof Dr Suleyman Yalcin Sehir Hastanesi

    Istanbul, 34722, Turkey (Türkiye)

  • Grand Hopital De Charleroi Site Les Viviers

    Charleroi, 6060, Belgium

  • Guys and St Thomas NHS Foundation Trust

    London, SE1 9RT, United Kingdom

  • GyeongSang National University Hospital

    Gyeongsangnam-do, 52727, South Korea

  • HCG Manavta Cancer Centre

    Nashik, 422002, India

  • Harbin medical university cancer hospital

    Harbin, 150000, China

  • Health Care Global Enterprises pvt Ltd

    Bangalore, 560027, India

  • Health Pharma Professional Research

    México, 03100, Mexico

  • Henan Cancer Hospital

    Zhengzhou, 450008, China

  • Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center

    Fort Lauderdale, Florida, 33308, United States

  • Hopital Nord

    Marseille, 13915, France

  • Hosp Clinic de Barcelona

    Barcelona, 08036, Spain

  • Hosp Regional Univ de Malaga

    Málaga, 29010, Spain

  • Hosp Univ A Coruna

    A Coruña, 15006, Spain

  • Hosp Univ Fund Jimenez Diaz

    Madrid, 28040, Spain

  • Hosp Univ Hm Sanchinarro

    Madrid, 28050, Spain

  • Hosp Univ Vall D Hebron

    Barcelona, 08035, Spain

  • Hosp. Gral. Univ. Gregorio Maranon

    Madrid, 28007, Spain

  • Hosp. Gral. Univ. Valencia

    Valencia, 46014, Spain

  • Hosp. Univ. 12 de Octubre

    Madrid, 28041, Spain

  • Hosp. Univ. I Politecni La Fe

    Valencia, 46026, Spain

  • Hosp. Univ. Insular de Gran Canaria

    Las Palmas de Gran Canaria, 35016, Spain

  • Hosp. Univ. La Paz

    Madrid, 28046, Spain

  • Hosp. Univ. Pta. de Hierro Majadahonda

    Majadahonda, 28222, Spain

  • Hosp. Univ. Quiron Dexeus

    Barcelona, 08028, Spain

  • Hosp. Virgen Del Rocio

    Seville, 41013, Spain

  • Hosp. de La Santa Creu I Sant Pau

    Barcelona, 08025, Spain

  • Hospices Civils de Lyon HCL

    Bron, 69500, France

  • Hospital Alemao Oswaldo Cruz

    São Paulo, 01327 001, Brazil

  • Hospital Civil de Guadalajara Fray Antonio Alcalde

    Guadalajara, 44280, Mexico

  • Hospital Ernesto Dornelles

    Porto Alegre, 90160-093, Brazil

  • Hospital Nove de Julho

    São Paulo, 01409902, Brazil

  • Hospital Paulistano

    São Paulo, 01323-000, Brazil

  • Hospital Privado Universitario De Cordoba

    Córdoba, X5016KEH, Argentina

  • Hospital Privado de la Comunidad

    Mar del Plata, B7602CBM, Argentina

  • Hospital Tengku Ampuan Afzan

    Kuantan, 25100, Malaysia

  • Huizhou Municipal Central Hospital

    Huizhou, 516001, China

  • Hunan Cancer hospital

    Changsha, 410013, China

  • Hunan Cancer hospital 1

    Changsha, 410013, China

  • Hyogo Cancer Center

    Hyōgo, 673-8558, Japan

  • IADT Instituto Argentino de Diagnostico y Tratamiento

    CABA, C1122, Argentina

  • IDOR - Regional Bahia

    Salvador, 41253-190, Brazil

  • IDOR - Regional Sao Paulo

    São Paulo, 01401 002, Brazil

  • IOS - Instituto de Oncologia de Sorocaba Dr. Gilson Delgado

    Sorocaba, 18030-005, Brazil

  • Institut Curie

    Paris, 75005, France

  • Institut Sainte Catherine

    Avignon, 84918, France

  • Instituto D Or de Pesquisa e Ensino IDOR

    Rio de Janeiro, 22281 100, Brazil

  • Instituto Nacional de Cancerologia

    México, 14080, Mexico

  • Instituto Portugues de Oncologia

    Porto, 4200072, Portugal

  • Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)

    Rio de Janeiro, 22775 001, Brazil

  • Istanbul University Cerrahpasa Medical Faculty

    Istanbul, 34098, Turkey (Türkiye)

  • Istituto Europeo di Oncologia

    Milan, 20141, Italy

  • Istituto Nazionale Tumori Regina Elena

    Roma, 00144, Italy

  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

    Meldola, 47014, Italy

  • Jessa Ziekenhuis - Campus Virga Jesse

    Hasselt, 3500, Belgium

  • Kaiser Permanente Northwest

    Portland, Oregon, 97227, United States

  • Kanagawa Cancer Center

    Kanagawa, 241-8515, Japan

  • Kaohsiung Medical University Chung Ho Memorial Hospital

    Kaohsiung City, 807, Taiwan

  • Klinikum der Universitaet Muenchen

    München, 80336, Germany

  • Kobe City Medical Center General Hospital

    Kobe, 650 0047, Japan

  • Korea University Anam Hospital

    Seoul, 02841, South Korea

  • Kurume University Hospital

    Kurume, 830-0011, Japan

  • Linkoping University Hospital

    Linköping, 581 85, Sweden

  • Llc, Eurocityclinic

    Saint Petersburg, 197022, Russia

  • McGill University Health Centre

    Montreal, Quebec, H4A 3J1, Canada

  • Medical Point

    Izmir, 35575, Turkey (Türkiye)

  • Medipol Mega University Hospital

    Istanbul, 34214, Turkey (Türkiye)

  • Meir Medical Center

    Kfar Saba, 44281, Israel

  • Memorial Ankara Hastanesi

    Ankara, 06520, Turkey (Türkiye)

  • Mount Miriam Cancer Hospital

    Tanjung Bungah, 11200, Malaysia

  • Multifunctional Hospital for Active Treatment 'Serdika'

    Sofia, 1303, Bulgaria

  • Multiprofile Hospital for Active Treatment 'Tokuda Hospital Sofia'

    Sofia, 1407, Bulgaria

  • Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy

    Warsaw, 02-781, Poland

  • National Cancer Center

    Gyeonggi-do, 10408, South Korea

  • National Cheng Kung University Hospital

    Tainan, 704, Taiwan

  • National Hospital Organization Iwakuni Clinical Center

    Yamaguchi, 740-8510, Japan

  • National Hospital Organization Nagoya Medical Center

    Nagoya, 460-0001, Japan

  • National Hospital Organization Shibukawa Medical Center

    Gunma, 377-0280, Japan

  • National Hospital Organization Yamaguchi Ube Medical Center

    Yamaguchi, 755-0241, Japan

  • National Taiwan University Hospital

    Taipei, 100, Taiwan

  • Nebraska Cancer Specialists

    Grand Island, Nebraska, 68803, United States

  • Niigata Cancer Center Hospital

    Niigata, 951-8566, Japan

  • Noble Hospital Pvt Ltd

    Pune, 411013, India

  • Norrlands Universitetssjukhus

    Umeå, 901 85, Sweden

  • NorthWest Medical Specialties, PLLC

    Puyallup, Washington, 98373, United States

  • Nouvel Hopital Civil - CHU Strasbourg

    Strasbourg, 67091, France

  • Nucleo de Oncologia da Bahia

    Salvador, 40170 110, Brazil

  • Oncoclinicas Rio de Janeiro S A

    Rio de Janeiro, 22250-905, Brazil

  • Oncologia Integral Satelite

    Naucalpan, 53100, Mexico

  • Oncologianova GmbH

    Recklinghausen, 45659, Germany

  • Oncology Consultants Texas

    Houston, Texas, 77030, United States

  • Onkologische Schwerpunktpraxis

    Heilbronn, 74072, Germany

  • Osaka International Cancer Institute

    Osaka, 541 8567, Japan

  • Ospedale S. Maria Delle Croci

    Ravenna, 48121, Italy

  • POIS Sachsen GmbH iG

    Leipzig, 04357, Germany

  • Pan American Center for Oncology Trials LLC

    Rio Piedras, 00917, Puerto Rico

  • Peking University People's Hospital

    Beijing, 100044, China

  • Policlinico G.B.Rossi

    Verona, 37134, Italy

  • Private Specialist Hospitals - MedPolonia

    Poznan, 60-693, Poland

  • Providence Portland Medical Center

    Portland, Oregon, 97213, United States

  • Queen Mary Hospital

    Hong Kong, 999077, Hong Kong

  • Rabin Medical Center

    Petah Tikva, 49100, Israel

  • Rajiv Gandhi Cancer Institute and Research Centre

    New Delhi, 110085, India

  • Rambam Health Corporation

    Haifa, 3109601, Israel

  • Real e Benemerita Associacao Portuguesa de Beneficencia

    São Paulo, 01323 900, Brazil

  • Rigshospitalet

    Copenhagen, DK 2100, Denmark

  • Rocky Mountain Cancer Centers

    Colorado Springs, Colorado, 80907, United States

  • Ruijin Hospital Shanghai Jiao Tong University

    Shanghai, 200025, China

  • Sahlgrenska Universitetssjukhuset

    Gothenburg, 413 45, Sweden

  • Samsung Medical Center

    Seoul, 06351, South Korea

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    Hangzhou, 310009, China

  • Seoul National University Bundang Hospital

    Gyeonggi-do, 13620, South Korea

  • Severance Hospital Yonsei University Health System

    Seoul, 03722, South Korea

  • Shaare Zedek Medical Center

    Jerusalem, 91031, Israel

  • Shanghai East Hospital

    Shanghai, 310000, China

  • Shenzhen university General Hospital

    Shenzhen, 518055, China

  • Shizuoka Cancer Center

    Shizuoka, 411 8777, Japan

  • Sichuan Cancer Hospital

    Chengdu, 610041, China

  • Sir Run Run Shaw Hospital Zhejiang University School of Medicine

    Hangzhou, 310016, China

  • Skanes universitetssjukhus

    Lund, 221 85, Sweden

  • Soroka University Medical Center

    Beersheba, 84101, Israel

  • Southern Cancer Center, PC

    Mobile, Alabama, 36608, United States

  • Southwest Hospital

    Chongqing, 400038, China

  • Specialized Hospital for Active Treatment in Oncology

    Sofia, 1756, Bulgaria

  • Subang Jaya Medical Centre

    Subang Jaya, 47500, Malaysia

  • Sun Yat-Sen Memorial Hospital Sun Yat-sen University

    Guangzhou, 510120, China

  • Szpitale Pomorskie Sp z o o

    Gdynia, 81 519, Poland

  • Taichung Veterans General Hospital

    Taichung, 40705, Taiwan

  • Taipei Medical University Shuang Ho Hospital

    New Taipei City, 23561, Taiwan

  • Taizhou Hospital of Zhejiang Province

    Linhai, 317000, China

  • Tata Medical Center

    Kolkata, 700160, India

  • Tata Memorial Hospital

    Mumbai, 400012, India

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, 6423906, Israel

  • Texas Oncology

    Grapevine, Texas, 76051, United States

  • Texas Oncology - Northeast

    Longview, Texas, 75601, United States

  • Texas Oncology Baylor Charles A Sammons Cancer Center

    Dallas, Texas, 75246, United States

  • Texas Oncology-Medical City Dallas

    Dallas, Texas, 75230, United States

  • The Cancer Institute Hospital of JFCR

    Tokyo, 135 8550, Japan

  • The Catholic University of Korea Seoul St Mary s Hospital

    Seoul, 06591, South Korea

  • The Christie Nhs Foundation Trust

    Manchester, M20 4BX, United Kingdom

  • The First Affiliated Hospital Sun Yat sen University

    Guangzhou, 510080, China

  • The First Affiliated Hospital of Xian Jiaotong University

    Xi'an, 710061, China

  • The Royal Marsden NHS Trust

    London, SW3 6JJ, United Kingdom

  • The Second Affiliated Hospital of Zhejiang University College of Medicine

    Hangzhou, 310009, China

  • Thoraxklinik am Universitatsklinikum Heidelberg

    Heidelberg, 69126, Germany

  • Tianjin Medical University General Hospital

    Tianjin, 300052, China

  • Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital

    Tokyo, 113 8677, Japan

  • Trakya University Medical Faculty

    Edirne, 22030, Turkey (Türkiye)

  • TriHealth Network

    Cincinnati, Ohio, 45220, United States

  • UMHAT Sofia Med

    Sofia, 1797, Bulgaria

  • UPCO Unidade de Pesquisa Clinica em Oncologia

    Pelotas, 96020 080, Brazil

  • UZ Gent

    Ghent, 9000, Belgium

  • UZ Leuven

    Leuven, 3000, Belgium

  • UZA

    Edegem, 2650, Belgium

  • Uls Loures Odivelas - Hosp. Loures

    Loures, 2674 514, Portugal

  • Uls Santa Maria - Hosp. Pulido Valente

    Lisbon, 1769-001, Portugal

  • Uls Santo Antonio - Hosp. Santo Antonio

    Porto, 4099-001, Portugal

  • Universitaetsklinikum Regensburg

    Regensburg, 93053, Germany

  • University Cancer And Blood Center LLC

    Athens, Georgia, 30607, United States

  • University College Hospital

    London, NW1 2PG, United Kingdom

  • University Malaya Medical Centre

    Kuala Lumpur, Malaysia

  • University of California Irvine

    Orange, California, 92868, United States

  • University of Mississippi Medical Center

    Jackson, Mississippi, 39216, United States

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, 15232, United States

  • University of Vermont Medical Center

    Burlington, Vermont, 05401, United States

  • University of Virginia

    Charlottesville, Virginia, 22908, United States

  • Uniwersyteckie Centrum Kliniczne

    Gdansk, 80 952, Poland

  • VUMC Amsterdam

    Amsterdam, 1081 HV, Netherlands

  • Velindre Hospital

    Cardiff, CF14 2TL, United Kingdom

  • Virginia Cancer Specialists

    Fairfax, Virginia, 22031, United States

  • Vitkovicka nemocnice a.s.

    Ostrava- Vitkovice, 70300, Czechia

  • Wakayama Medical University Hospital

    Wakayama, 641 8510, Japan

  • Warminsko-Mazurskie Centrum Chorob Pluc w Olsztynie

    Olsztyn, 10-357, Poland

  • Weifang People's Hospital

    Weifang, 261000, China

  • West China Hospital Sichuan University

    Chengdu, 610041, China

  • Wielkopolskie Centrum Pulmonologii i Torakochirurgii im. Eugenii i Janusza Zeylandow

    Poznan, 60 569, Poland

  • Yantai Yuhuangding Hospital

    Yantai, 264000, China

  • Ynova Pesquisa Clinica

    Florianópolis, 88020-210, Brazil

  • Zhejiang Cancer Hospital

    Hangzhou, 310022, China

  • Ziekenhuis St Jansdal

    Harderwijk, 3844 DG, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.